Bill > A03833

This bill requires various insurance providers, including individual and group policies, medical expense indemnity corporations, hospital and health service corporations, and medical assistance programs, to provide coverage for COVID-19 antiviral therapeutics that have been approved or granted emergency use authorization by the Food and Drug Administration (FDA) at no cost to the patient. Specifically, the coverage must be prescribed by a licensed healthcare provider legally authorized to prescribe medications, and it cannot be subject to annual deductibles or coinsurance. However, if a patient is eligible to obtain these therapeutics at no or reduced cost through a manufacturer or government program, they may be required to use that program first before utilizing the insurance coverage. The bill will take effect on the first day of January following its enactment and will apply to all insurance policies and contracts issued, renewed, modified, altered, or amended on or after that date, ensuring that patients have access to potentially life-saving COVID-19 treatments without additional financial burden.

Business and Industry

https://www.nysenate.gov/legislation/bills/2025/A3833